borderline stenosis
Conditions
Interventions
Treatment group:Xuanbi Antong Granules
Placebo group:Placebo
Sponsors
Guang'anmen Hospital,China Academy of Chinese Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Coronary CT or coronary arteriography shows that diameter stenosis is from 30 percent to 70 percent and have not been given PCI or CABG; 2. Patients who are diagnosed as coronary atherosclerotic heart disease; 3. Patients who are diagnosed as phlegm, blood stasis and heat syndrome by TCM; 4. Patients who are older than 30 and younger than 75; 5. Patients agree to the study protocol and provide informed, written consent.;Inclusion criteria: 1. Coronary CT or coronary arteriography shows that diameter stenosis is from 30 percent to 70 percent and have not been given PCI or CABG; 2. Patients who are diagnosed as coronary atherosclerotic heart disease; 3. Patients who are diagnosed as phlegm, blood stasis and heat syndrome by TCM; 4. Patients who are older than 30 and younger than 75; 5. Patients agree to the study protocol and provide informed, written consent.;Inclusion criteria: 1. Coronary CT or coronary arteriography shows that diameter stenosis is from 30 percent to 70 percent and have not been given PCI or CABG; 2. Patients who are diagnosed as coronary atherosclerotic heart disease; 3. Patients who are diagnosed as phlegm, blood stasis and heat syndrome by TCM; 4. Patients who are older than 30 and younger than 75; 5. Patients agree to the study protocol and provide informed, written consent.;Inclusion criteria: 1. Coronary CT or coronary arteriography shows that diameter stenosis is from 30 percent to 70 percent and have not been given PCI or CABG; 2. Patients who are diagnosed as coronary atherosclerotic heart disease; 3. Patients who are diagnosed as phlegm, blood stasis and heat syndrome by TCM; 4. Patients who are older than 30 and younger than 75; 5. Patients agree to the study protocol and provide informed, written consent.;Inclusion criteria: 1. Coronary CT or coronary arteriography shows that diameter stenosis is from 30 percent to 70 percent and have not been given PCI or CABG; 2. Patients who are diagnosed as coronary atherosclerotic heart disease; 3. Patients who are diagnosed as phlegm, blood stasis and heat syndrome by TCM; 4. Patients who are older than 30 and younger than 75; 5. Patients agree to the study protocol and provide informed, written consent.
Exclusion criteria
Exclusion criteria: 1. Chest pain caused by severe left main coronary artery lesions, severe valvular heart disease (aortic stenosis), severe psychoneurosis, climacteric syndrome, hyperthyroidism, cervical spondylosis, gallbladder heart syndrome, gastroesophageal reflux disease; 2. Uncontrolled hypertension with SBP=160mmHg or DBP=100mmHg, severe cardiac insufficiency with EF<35%, severe arrhythmia (Fast Atrial Fibrillation, Atrial Flutter, paroxysmal ventricular tachycardia, atrioventricular block higher that second degree subtype II, complete bundle branch block); 3. Patients with severe primary diseases like heart, brain, liver, kidney, hemopoietic system related diseases, and patients whose ALT or AST is higher than 1.5 times of the upper limit, patients with abnormal renal function or insulin dependent diabetes mellitus; 4. Patients with depression or anxiety; 5. Stroke or resuscitated sudden death in the past 6 months; 6. Hyperthyroidism with TSH levels more than 1.5 times upper limit of narmal; 7. Patients with malignant tumor; 8. Pregnant women or breast feeding women; 9. Reference vessel diameter of the target vessel < 2.5mm, or there is no non-calcified plaque in the main coronary artery, or severe tortuosity of the target vessel or any other anatomical reasons that the investigator deems inappropriate for CTA procedure; 10. Chronic disease requiring treatment with oral, intravenous, or intra-articular corticosteroids (use of topical, inhaled, or nasal corticosteroids is permissible); 11. Patients with allergic constitution or are allergic to many kinds of TCM herbs and Iodine; 12. Patients with low compliance, who might miss the follow-up; 13. Patients who participant in other clinical trials in last 1 month.;Exclusion criteria: 1. Chest pain caused by severe left main coronary artery lesions, severe valvular heart disease (aortic stenosis), severe psychoneurosis, climacteric syndrome, hyperthyroidism, cervical spondylosis, gallbladder heart syndrome, gastroesophageal reflux disease; 2. Uncontrolled hypertension with SBP=160mmHg or DBP=100mmHg, severe cardiac insufficiency with EF<35%, severe arrhythmia (Fast Atrial Fibrillation, Atrial Flutter, paroxysmal ventricular tachycardia, atrioventricular block higher that second degree subtype II, complete bundle branch block); 3. Patients with severe primary diseases like heart, brain, liver, kidney, hemopoietic system related diseases, and patients whose ALT or AST is higher than 1.5 times of the upper limit, patients with abnormal renal function or insulin dependent diabetes mellitus; 4. Patients with depression or anxiety; 5. Stroke or resuscitated sudden death in the past 6 months; 6. Hyperthyroidism with TSH levels more than 1.5 times upper limit of narmal; 7. Patients with malignant tumor; 8. Pregnant women or breast feeding women; 9. Reference vessel diameter of the target vessel < 2.5mm, or there is no non-calcified plaque in the main coronary artery, or severe tortuosity of the target vessel or any other anatomical reasons that the investigator deems inappropriate for CTA procedure; 10. Chronic disease requiring treatment with oral, intravenous, or intra-articular corticosteroids (use of topical, inhaled, or nasal corticosteroids is permissible); 11. Patients with allergic constitution or are allergic to many kinds of TCM herbs and Iodine; 12. Patients with low compliance, who might miss the follow-up; 13. Patients who participant in other clinical trials in last 1 month.;Exclusion criteria: 1. Chest pain caused by severe left main coronary artery lesions, severe valvular heart disease (aortic stenosis), severe psychoneurosis, climacteric syndrome, hyperthyroidism, cervical spondylosis, gallbladder heart syndrome, gastroesophageal reflux disease; 2. Uncontrolled hypertension with SBP=160mmHg or DBP=100mmHg, severe cardiac insufficiency with EF<35%, severe arrhythmia (Fast Atrial Fibrillation, Atrial Flutter, paroxysmal ventricular tachycardia, atrioventricular block higher that second degree subtype II, complete bundle branch block); 3. Patients with severe primary diseases like heart, brain, liver, kidney, hemopoietic system related diseases, and patients whose ALT or AST is higher than 1.5 times of the upper limit, patients with abnormal renal function or insulin dependent diabetes mellitus; 4. Patients with depression or anxiety; 5. Stroke or resuscitated sudden death in the past 6 months; 6. Hyperthyroidism with TSH levels more than 1.5 times upper limit of narmal; 7. Patients with malignant tumor; 8. Pregnant women or breast feeding women; 9. Reference vessel diameter of the target vessel < 2.5mm, or there is no non-calcified plaque in the main coronary artery, or severe tortuosity of the target vessel or any other anatomical reasons that the investigator deems inappropriate for CTA procedure; 10. Chronic disease requiring treatment with oral, intravenous, or intra-articular corticosteroids (use of topical, inhaled, or nasal corticosteroids is permissible); 11. Patients with allergic constitution or are allergic to many kinds of TCM herbs and Iodine; 12. Patients with low compliance, who might miss the follow-up; 13. Patients who participant in other clinical trials in last 1 month.;Exclusion criteria: 1. Chest pain caused by severe left main coronary artery lesions, severe valvular heart disease (aortic stenosis), severe psychoneurosis, climacteric syndrome, hyperthyroidism, cervical spondylosis, gallbladder heart syndrome, gastroesophageal reflux disease; 2. Uncontrolled hypertension with SBP=160mmHg or DBP=100mmHg, severe cardiac insufficiency with EF<35%, severe arrhythmia (Fast Atrial Fibrillation, Atrial Flutter, paroxysmal ventricular tachycardia, atrioventricular block higher that second degree subtype II, complete bundle branch block); 3. Patients with severe primary diseases like heart, brain, liver, kidney, hemopoietic system related diseases, and patients whose ALT or AST is higher than 1.5 times of the upper limit, patients with abnormal renal function or insulin dependent diabetes mellitus; 4. Patients with depression or anxiety; 5. Stroke or resuscitated sudden death in the past 6 months; 6. Hyperthyroidism with TSH levels more than 1.5 times upper limit of narmal; 7. Patients with malignant tumor; 8. Pregnant women or breast feeding women; 9. Reference vessel diameter of the target vessel < 2.5mm, or there is no non-calcified plaque in the main coronary artery, or severe tortuosity of the target vessel or any other anatomical reasons that the investigator deems inappropriate for CTA procedure; 10. Chronic disease requiring treatment with oral, intravenous, or intra-articular corticosteroids (use of topical, inhaled, or nasal corticosteroids is permissible); 11. Patients with allergic constitution or are allergic to many kinds of TCM herbs and Iodine; 12. Patients with low compliance, who might miss the follow-up; 13. Patients who participant in other clinical trials in last 1 month.;Exclusion criteria: 1. Chest pain caused by severe left main coronary artery lesions, severe valvular heart disease (aortic stenosis), severe psychoneurosis, climacteric syndrome, hyperthyroidism, cervical spondylosis, gallbladder heart syndrome, gastroesophageal reflux disease; 2. Uncontrolled hypertension with SBP=160mmHg or DBP=100mmHg, severe cardiac insufficiency with EF<35%, severe arrhythmia (Fast Atrial Fibrillation, Atrial Flutter, paroxysmal ventricular tachycardia, atrioventricular block higher that second degree subtype II, complete bundle branch block); 3. Patients with severe primary diseases like heart, brain, liver, kidney, hemopoietic system related diseases, and patients whose ALT or AST is higher than 1.5 times of the upper limit, patients with abnormal renal function or insulin dependent diabetes mellitus; 4. Patients with depression or anxiety; 5. Stroke or resuscitated sudden death in the past 6 months; 6. Hyperthyroidism with TSH levels more than 1.5 times upper limit of narmal; 7. Patients with malignant tumor; 8. Pregnant women or breast feeding women; 9. Reference vessel diameter of the target vessel < 2.5mm, or there is no non-calcified plaque in the main coronary artery, or severe tortuosity of the target vessel or any other anatomical reasons that the investigator deems inappropriate for CTA procedure; 10. Chronic disease requiring treatment with oral, intravenous, or intra-articular corticosteroids (use of topical, inhaled, or nasal corticosteroids is permissible); 11. Patients with allergic constitution or are allergic to many kinds of TCM herbs and Iodine; 12. Patients with low compliance, who might miss the follow-up; 13. Patients who participant in other clinical trials in last 1 month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| index of plaque by MSCT;TC, TG, LDL, HDL; | — |
Secondary
| Measure | Time frame |
|---|---|
| withdrawal and decreasing rate of nitroglycerin;ECG;angina frequency;SAQ;MACE;secondary ACE; | — |
Countries
China
Contacts
Public ContactJie Wang;Jie Wang;Jie Wang;Jie Wang;Jie Wang ;;;;
Guang'anmen Hospital, China Academy of Chinese Medical Sciences;Guang'anmen Hospital, China Academy of Chinese Medical Sciences;Guang'anmen Hospital, China Academy of Chinese Medical Sciences;Guang'anmen Hospital, China Academy of Chinese Medical Sciences;Guang'anmen Hospital, China Academy of Chinese Medical Sciences
Outcome results
None listed